Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Electronics Takes Step Into Korea's Biosimilar Foray With IND For MabThera Generic

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's electronics and semiconductor giant Samsung Electronics has submitted an investigational new drug application to Korea FDA to conduct clinical trials for its biosimilar of Roche's MabThera.

You may also be interested in...



Korea FDA OKs Samsung's Clinical Trial Application For Roche's MabThera Biosimilar

SEOUL - Korea FDA approved March 8 Samsung Electronics' investigational new drug application to commence Phase I clinical trials of a biosimilar of Roche's MabThera, marking the first step of the electronics and semiconductor giant's ambition to enter the healthcare sector

Korea FDA OKs Samsung's Clinical Trial Application For Roche's MabThera Biosimilar

SEOUL - Korea FDA approved March 8 Samsung Electronics' investigational new drug application to commence Phase I clinical trials of a biosimilar of Roche's MabThera, marking the first step of the electronics and semiconductor giant's ambition to enter the healthcare sector

Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV

Samsung plans to begin construction on its manufacturing plant in Incheon during the first half of this year, and production is expected to commence in the first half of 2013.

Related Content

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel